arrow
N

Nikolaos Tsoukalas

401 general military hospital of athens
H指数:24
被引数:2,198

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Toxicity and Effectiveness Study of Abemaciclib in Greek Patients with Hormone Receptor-Positive-Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Multi-Institutional Study

希腊激素受体阳性-人表皮生长因子受体2阴性乳腺癌患者中阿贝西利片的真实世界毒性和有效性研究:一项多中心研究

2025-08-200
PRE
Analysis of evolution of patient reported side effects during treatment for advanced NSCLC

对晚期非小细胞肺癌治疗期间患者报告的不良反应演变分析

2024-09-010
PRE
Testing HR+ / HER2-patients with advanced or metastatic breast cancer for identification of tissue mutations in the PIK3CA gene: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO)
2023-10-010
OA
Clinical and molecular study with digital support of advanced non-small cell lung cancer patients: SNF-CLIMEDIN, a prospective randomized Hellenic Cooperative Oncology Group (HeCOG) study: Interim analysis

晚期非小细胞肺癌患者数字支持的临床和分子研究: snf-climedin,一项前瞻性随机希腊肿瘤协作组 (HeCOG) 研究: 中期分析

2023-10-011
OAAI
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease

肺癌合并慢性阻塞性肺疾病诊治国际专家共识

2023-08-019
OAAI
Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry

精确肿瘤学时代EGFR外显子20突变NSCLC患者的分子流行病学和治疗模式: 欧洲异国注册中心

2023-01-0114
OA
Safety and efficacy of immunotherapy rechallenge following checkpoint inhibitor-related pneumonitis in advanced lung cancer patients: a retrospective multi-center cohort study
2022-11-0112
OAAI
Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study

Patras免疫治疗评分模型对nivolumab或pembrolizumab治疗晚期NSCLC患者的预测和预后的验证: 来自欧洲多中心研究的结果

2022-09-081
OAAI
Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis
2022-07-208
OAAI
Should patients with active gastrointestinal tumors receive thromboprophylaxis to avoid the negative clinical consequences of CAT? Sub-analysis of ACT4CAT study
2021-07-010
OAAI